Pulse Biosciences stockholders approve equity plan amendment and ratify executive option grants

PULSE BIOSCIENCES, INC.

Proposal 1 (increase share reserve by 1,375,000 shares) passed with 38.3M for, 2.97M against.
Proposal 2 (ratify options for 1,505,000 shares at $4.38) passed with 39.2M for, 2.06M against.
Ratified options include grants to CEO Kevin Danahy (460,000), Darrin Uecker (330,000), Mitchell Levinson (100,000).
Options have 10-year term, vest at 6-year anniversary or 1-year after change in control.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

PULSE BIOSCIENCES, INC. shareholders approved Approve amendment to 2017 Equity Incentive Plan to increase shares by 1,375,000 at the 2023-12-19 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-12-19

Exact text from the filing

Proposal 1. Amendment of the Equity Plan For Against Abstained Broker Non-votes 38,301,130 2,970,156 4,396 N/A

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

PULSE BIOSCIENCES, INC. shareholders approved Ratify options awarded on November 1, 2023 under the Equity Plan at the 2023-12-19 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-12-19

Exact text from the filing

Proposal 2. Ratification of Award For Against Abstained Broker Non-votes 39,206,759 2,064,323 4,600 N/A

View on SEC.gov

Browse all shareholder votes →

PULSE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-035170

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.